-
Press Release
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
-
Press Release
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
-
Press Release
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
-
Press Release
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
-
Press Release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
-
Press Release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
-
Press Release
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
-
Press Release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
-
Press Release
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
-
Press Release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
-
Press Release
Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut
-
Press Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting